New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
17:05 EDTGEVA, RGEN, NFLX, SNY, GPRO, AYI, TWTROn The Fly: Closing Wrap
Stocks on Wall Street were higher but the Dow will need to wait at least one more session before eclipsing 17,000 for the first time. The bluechip average, along with the S&P 500 and the Nasdaq, began the trading day in positive territory and remained there for the entire session. Following manufacturing reports from around the globe that were released today, investors will now be keying in on the week's big economic event, which is the U.S. monthly nonfarm payrolls report due Thursday. ECONOMIC EVENTS: In the U.S., Markit's manufacturing purchasing managers' index for June had a final reading of 57.3, which was a hair below the 57.5 flash estimate but up from May's 56.4 reading. ISM's manufacturing index slipped very slightly to 55.3 in June from May's 55.4 figure. Construction spending increased 0.1% in May, missing the forecast for 0.5% growth. In China, HSBC's PMI reading came in at 50.7, which was a bit below the flash reading but above the 50 mark that indicates expansion for the first time since December. In Europe, Markit's final eurozone manufacturing PMI for June came in at 51.8, which was down from 52.2 in the prior month and below the earlier flash estimate of 51.9, but still indicated expansion in the sector. COMPANY NEWS: Shares of Netflix (NFLX) climbed $32.50, or 7.38%, to $473.10 after Goldman Sachs upgraded the stock in a note to investors earlier today, predicting that Netflix's total worldwide market will more than double over the next three years and its subscriber growth will continue to exceed expectations... Twitter (TWTR) rose $1.08, or 2.64%, to $42.05 after hiring Anthony Noto as its new Chief Financial Officer. Noto served as a Managing Director in the Technology, Media and Telecom group at Goldman Sachs (GS), which had handled the social network's IPO, and prior to that had served as the CFO of the National Football League. MAJOR MOVERS: Among the notable gainers was GoPro (GPRO), which rose another $8.25, or 20.35%, to $48.80 in its fourth trading session since its IPO last Thursday. The action camera maker has advanced an incredible 66.78% since its IPO priced at $24.00 per share. Also higher was Regeneron (REGN), which advanced $20.92, or 7.41%, to $303.39 after Sanofi (SNY) disclosed in a regulatory filing that it plans to increase its beneficial ownership stake in its smaller pharmaceutical industry peer to 22.5% from 20.5%. Among the noteworthy losers was lighting solutions maker Acuity Brands (AYI), which fell $20.63, or 14.92%, to $117.62 after its sales and profits missed expectations. Also lower were shares of Synageva BioPharma (GEVA), which tumbled $14.35, or 13.69%, to $90.45 after the company reported that its sebelipase alfa drug had met its primary endpoint in a trial, but two research firms were lukewarm about the stock's outlook. INDEXES: The Dow was up 129.47, or 0.77%, to 16,956.07, the Nasdaq was up 50.47, or 1.14%, to 4,458.65, and the S&P 500 was up 13.09, or 0.67%, to 1,973.32.
News For NFLX;TWTR;GPRO;RGEN;AYI;SNY;GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 13, 2015
07:16 EDTNFLXMoffett Nathanson to hold a summit
Subscribe for More Information
07:05 EDTSNYSanofi exercises option on therapeutic program with Selecta Biosciences
Selecta Biosciences., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi. November 2012, Selecta announced that they had formed a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life threatening allergies. Under the agreement, Sanofi obtained a first exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies and celiac disease. With the exercise of this option by Sanofi, Selecta and Sanofi now have two initiatives actively advancing immune tolerance treatments under the terms of the 2012 agreement. In October 2014, Selecta and JDRF announced another collaboration with Sanofi to research novel antigen-specific immune therapies for Type 1 Diabetes.
06:55 EDTNFLXInsiders speculate bidding war to erupt over AOL, Business Insider reports
The consensus speculation from investment bankers, hedge fund traders and people close to AOL (AOL) is that another company will emerge and offer a price for AOL that is higher than $50 per share, reports Business Insider. The potential suitors include Time Warner (TWX), Comcast (CMCSA), Yahoo (YHOO), Alibaba (BABA), Softbank (SFTBF), AT&T (T), Netflix (NFLX) and Apple (AAPL). Reference Link
06:50 EDTAYIAcuity Brands price target raised to $207 from $194 at Piper Jaffray
Piper Jaffray raised its price target for Acuity Brands to $207 saying its seeing "positive and steady" improvement in several lighting end markets. Piper expects further market share gains to drive shares higher and keeps an Overweight rating on Acuity.
May 12, 2015
16:01 EDTTWTROptions Update; May 12, 2015
Subscribe for More Information
12:34 EDTRGENOn The Fly: Top stock stories at midday
Subscribe for More Information
11:37 EDTTWTRStocks with call strike movement; TWTR JCP
Subscribe for More Information
10:45 EDTRGENAnalyst says Pall deal may spark more life sciences M&A
Subscribe for More Information
09:51 EDTRGENPall Corp. could be precursor to more Life Science deals, says Janney Capital
After The Wall Street Journal said Pall Corp. (PLL) is nearing a possible sale, naming Thermo Fisher (THO) and Danaher (DHR) as potential suitors, Janney Capital said it thinks dealmaking in the Life Sciences space won't stop with Pall, listing Repligen (RGEN), Bio-Techne (TECH) and VWR (VWR) as others in the industry that could see strategic bids emerge. The firm added that it expects that GE (GE), 3M (MMM), and private equity firms would also be involved in bidding in deals in the space.
09:38 EDTNFLX, TWTRActive equity options trading on open
Subscribe for More Information
09:14 EDTGPROApps World to hold a conference
Subscribe for More Information
08:07 EDTNFLXSunTrust to hold a conference
Subscribe for More Information
07:52 EDTGEVALeerink to hold a tour
Subscribe for More Information
06:09 EDTTWTRTwitter spent over $85M to buy Periscope, Niche, Re/code reports
Twitter paid over $86M to buy Periscope, a live streaming app, and Niche, a social media talent agency, earlier this year, Re/code reports. Re/code previously said Twitter acquired Niche for approximately $30M, including earn-out payments. Reference Link
06:03 EDTGPROGoPro implied volatility of 49 at lower end of index mean range
Subscribe for More Information
06:02 EDTNFLXStocks with implied volatility below IV index mean; LNKD NFLX
Subscribe for More Information
May 11, 2015
16:00 EDTTWTR, NFLXOptions Update; May 11, 2015
Subscribe for More Information
11:23 EDTTWTRStocks with call strike movement; TWTR TSLS
Subscribe for More Information
10:35 EDTGPROWellington lowers passive stake in GoPro to 6.27% from 12%
Subscribe for More Information
06:33 EDTNFLXTV networks worried amid tough competition from digital outlets, NY Times says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use